Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients.
Mental illness takes a heavy personal toll on the patients, caregivers and loved ones who are impacted. According to the National Institute of Mental Health, one in five people or 46.6 million Americans have a mental illness. The economic impact is also significant with resulting lost wages, health care expenditures and disability benefits costing the U.S. more than $317 billion annually.
The development of new and effective treatments for mental illness is very difficult, given the scientific complexities underlying the cause of many of these diseases. Despite these challenges, today biopharmaceutical research companies have 138 medicines in development which offer a promise to help the millions of Americans living with mental illness.
The medicines in development include:
- 40 for depression, including major depressive disorder which affects 7.1% of adults and 13.3% of adolescents aged 12 to 17 in the U.S. More than 70% of people suffering from depression have not received any kind of treatment. Approximately one-third of adults with major depression have treatment resistant depression where currently available treatments provide little to no relief, representing a significant unmet need.
- 38 for schizophrenia, which affects less than 1% of U.S. adults. Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. This disease in particular is especially debilitating as it can result in psychotic behaviors like hallucinations and other disruptions to normal emotions and behaviors.
- 27 for substance use disorders. Nearly 29 million Americans aged 12 and older (10.6% of the U.S. population) have reported using an illicit drug in the past month and 8.5 million adults in the U.S. have both a substance use disorder and a mental illness. The presence of co-occurring mental illness and substance use disorders can increase symptom severity, complicate treatment and create medication adherence challenges.
- 18 for anxiety disorders, which impacts more than a third of adults and adolescents in the U.S. during their lifetime. There are several types of anxiety disorders, including, generalized anxiety disorder, panic disorder, phobia-related disorders (e.g., the fear of flying, heights or needles), social anxiety disorder and separation anxiety disorder.
- 17 for attention-deficit/hyperactivity disorder (ADHD), which affects 4.4% of U.S. adults and 8.7% of adolescents aged 13 to 18. ADHD is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
- 11 for bipolar disorders, which affect about 2.8% of adults and 2.9% of adolescents in the U.S. Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels and the ability to carry out day-to-day tasks.
The development of new and effective treatments for patients with mental illness is very challenging. But biopharmaceutical researchers are making strides in the world of mental illness by expanding the understanding of the underlying causes of these diseases and bringing about a new era in the treatment of mental illness. Now, more than ever, we understand that the appropriate treatment of mental health conditions, once they are first recognized, can change the trajectory of an individual’s life for the better.
To read the new report on medicines in development for mental illness, click here.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Advancing mental health in May and beyond
World Mental Health Day: Supporting access to medicines that help loved ones
The role of antidepressants in addressing America’s mental health crisis
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
Women’s Health Month: A conversation with Sage
New Report: 1,600 cancer treatments and vaccines in clinical development
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New paper: Addressing the growing crisis of mental health and substance use disorders
Mental Illness Awareness Week – A time for reflection
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Potential gene therapies bring hope to patients with sickle cell disease
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Spotlighting a growing mental health challenge
A conversation with Barry Greene, CEO of Sage Therapeutics
Report: More than 600 medicines in development for diseases affecting women
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
New Report: Nearly 800 new medicines in development to treat rare diseases
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
Reflecting on Mental Health Awareness Month
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
Action needed to preserve the six protected classes
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest Post: Recognizing America’s Veterans
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
Guest post: A post-pandemic crisis: The mental toll on America
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
New report finds 15 new oncology therapies launched last year
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Event: New era of medicine comes to Capitol Hill
New report shows more than 160 medicines in development for diabetes and related conditions
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
Disrupting Alzheimer's
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
Rare Disease Day: Unmet need inspires innovation
New report shows 200 medicines in development for heart disease and stroke
ICYMI: Why 2017 medicine approvals matter
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
New report and event examine the new era of vaccines
A new era in cancer
2017 Research & Hope Awards honor innovators in mental health
How biopharmaceutical collaboration is driving a new era of medicine
Medicare Monday: Strengthening access to vaccines for seniors
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Finding cures for incurable diseases
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Examining the brain in The New Era of Medicine
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
Opening the conversation around mental health treatment with advocates & industry leaders
More than 240 immuno-oncology treatments in development to fight cancer
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
Mental health in the New Era of Medicine
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
Nearly 140 medicines in development to treat mental illness
Medicines in Development
New Era of Medicine
Mental Health
Nearly 140 medicines in development to treat mental illness
Nearly 140 medicines in development to treat mental illness